FDA Grants Priority Review to Sarclisa for Treating Newly Diagnosed Multiple Myeloma in Transplant-Ineligible Patients (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-grants-priority-review-sarclisa-ndmm)